These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 29243491)

  • 1. Immunogenicity of therapeutic protein products: current considerations for anti-drug antibody assay in Japan.
    Ishii-Watabe A; Shibata H; Nishimura K; Hosogi J; Aoyama M; Nishimiya K; Saito Y
    Bioanalysis; 2018 Jan; 10(2):95-105. PubMed ID: 29243491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Report on the AAPS Immunogenicity Guidance Forum.
    Myler H; Gorovits B; Phillips K; Devanarayan V; Clements-Egan A; Gunn GR; Kirshner S; DeSilva B; Shah VP
    AAPS J; 2019 Apr; 21(4):55. PubMed ID: 30993501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elucidation of the statistical factors that influence anti-drug antibody cut point setting through a multi-laboratory study.
    Nishimura K; Shibata H; Aoyama M; Hosogi J; Kadotsuji K; Minoura K; Mori T; Nakamura T; Nishimiya K; Nomura T; Saito T; Soma M; Wakabayashi H; Sakamoto N; Niimi S; Katori N; Saito Y; Ishii-Watabe A
    Bioanalysis; 2019 Mar; 11(6):509-524. PubMed ID: 30945932
    [No Abstract]   [Full Text] [Related]  

  • 4. Quartz crystal microbalance as an assay to detect anti-drug antibodies for the immunogenicity assessment of therapeutic biologics.
    Dubiel EA; Fülöp T; Vigier S; Vermette P
    Anal Bioanal Chem; 2017 Dec; 409(30):7153-7167. PubMed ID: 29026983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-normal random effects models for immunogenicity assay cut point determination.
    Zhang J; Yu B; Zhang L; Roskos L; Richman L; Yang H
    J Biopharm Stat; 2015; 25(2):295-306. PubMed ID: 25356500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating and Reporting the Immunogenicity Impacts for Biological Products--a Clinical Pharmacology Perspective.
    Wang YM; Wang J; Hon YY; Zhou L; Fang L; Ahn HY
    AAPS J; 2016 Mar; 18(2):395-403. PubMed ID: 26721560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recommendations for the Development and Validation of Immunogenicity Assays in Support of Biosimilar Programs.
    Civoli F; Kasinath A; Cai XY; Wadhwa M; Exley A; Oldfield P; Alvandkouhi S; Schaffar G; Chappell J; Bowsher R; Devanarayan V; Marini J; Rebarchak S; Anderson M; Koppenburg V; Lester T
    AAPS J; 2019 Dec; 22(1):7. PubMed ID: 31792633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-drug Antibody Assay Conditions Significantly Impact Assay Screen and Confirmatory Cut-Points.
    Gorovits B; Wang Y; Zhu L; Araya M; Kamerud J; Lepsy C
    AAPS J; 2019 Jun; 21(4):71. PubMed ID: 31161482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A survey of applications of biological products for drug interference of immunogenicity assays.
    Wang YM; Fang L; Zhou L; Wang J; Ahn HY
    Pharm Res; 2012 Dec; 29(12):3384-92. PubMed ID: 22903525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding the Supersensitive Anti-Drug Antibody Assay: Unexpected High Anti-Drug Antibody Incidence and Its Clinical Relevance.
    Song S; Yang L; Trepicchio WL; Wyant T
    J Immunol Res; 2016; 2016():3072586. PubMed ID: 27340678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics.
    Gorovits B; Wakshull E; Pillutla R; Xu Y; Manning MS; Goyal J
    J Immunol Methods; 2014 Jun; 408():1-12. PubMed ID: 24861938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of competitive ligand-binding assay and bioassay formats for the measurement of neutralizing antibodies to protein therapeutics.
    Finco D; Baltrukonis D; Clements-Egan A; Delaria K; Gunn GR; Lowe J; Maia M; Wong T
    J Pharm Biomed Anal; 2011 Jan; 54(2):351-8. PubMed ID: 20863644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategic characterization of anti-drug antibody responses for the assessment of clinical relevance and impact.
    Tatarewicz SM; Mytych DT; Manning MS; Swanson SJ; Moxness MS; Chirmule N
    Bioanalysis; 2014 Jun; 6(11):1509-23. PubMed ID: 25046051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An immunoinhibition approach to overcome the impact of pre-existing antibodies on cut point establishment for immunogenicity assessment of moxetumomab pasudotox.
    Schneider AK; Vainshtein I; Roskos LK; Chavez C; Sun B; Liang M
    J Immunol Methods; 2016 Aug; 435():68-76. PubMed ID: 27220271
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Ito S; Ikuno T; Mishima M; Yano M; Hara T; Kuramochi T; Sampei Z; Wakabayashi T; Tabo M; Chiba S; Kubo C
    J Immunotoxicol; 2019 Dec; 16(1):125-132. PubMed ID: 31179789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic study of the effect of low pH acid treatment on anti-drug antibodies specific for a domain antibody therapeutic: Impact on drug tolerance, assay sensitivity and post-validation method assessment of ADA in clinical serum samples.
    Kavita U; Duo J; Crawford SM; Liu R; Valcin J; Gleason C; Dong H; Gadkari S; Dodge RW; Pillutla RC; DeSilva BS
    J Immunol Methods; 2017 Sep; 448():91-104. PubMed ID: 28625864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products.
    Shankar G; Devanarayan V; Amaravadi L; Barrett YC; Bowsher R; Finco-Kent D; Fiscella M; Gorovits B; Kirschner S; Moxness M; Parish T; Quarmby V; Smith H; Smith W; Zuckerman LA; Koren E
    J Pharm Biomed Anal; 2008 Dec; 48(5):1267-81. PubMed ID: 18993008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation.
    Jawa V; Cousens LP; Awwad M; Wakshull E; Kropshofer H; De Groot AS
    Clin Immunol; 2013 Dec; 149(3):534-55. PubMed ID: 24263283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toward comparability of anti-drug antibody assays: is the amount of anti-drug antibody-reagent complexes at cut-point (CP-ARC) the missing piece?
    Jordan G; Staack RF
    Bioanalysis; 2020 Jul; 12(14):1021-1031. PubMed ID: 32633539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of Therapeutic Antibodies: Monitoring Antidrug Antibodies in a Clinical Context.
    Bloem K; Hernández-Breijo B; Martínez-Feito A; Rispens T
    Ther Drug Monit; 2017 Aug; 39(4):327-332. PubMed ID: 28463887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.